Pulmonology Medical News about lung cancer

Your Unread Messages

See All

Hello, Mary O'connor
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer
Lung Cancer, 10/30/09

Kaira K et al. – Amrubicin is an active and well–tolerated regimen in patients with previously treated lung cancer. Amrubicin 35mg/m2 seems to achieve similar efficacy with less toxicity than amrubicin 40mg/m2 in this patient population. These results warrant further evaluation in previously treated lung cancer.

<< Previous
Hemodynamic and Gas Exchange Effects of Sildenafil in Patients...

Next >>
Clinical evaluation of the QuantiFERON-TB Gold test in patients...

Lung cancer: a biologically different disease in women?
Women's Health, 10/30/09 Relevance Score: 73%

Oestrogen plus progestin and lung cancer in postmenopausal women (Womens Health Initiative trial): a post-hoc analysis of a randomised controlled trial
The Lancet, 10/12/09 Relevance Score: 72%

Haplotype and Cell Proliferation Analyses of Candidate Lung Cancer Susceptibility Genes on Chromosome 15q24-25.1
Cancer Research, 10/06/09 Relevance Score: 71%

Noninvasive detection of lung cancer by analysis of exhaled breath
BMC Cancer, 10/09/09 Relevance Score: 70%

African American lung cancer patients may have different response to new cancer-fighting drugs
EurekAlert, 10/08/09 Relevance Score: 70%